IKNA - Optimism Surrounds Cancer Focused Ikena Oncology Analyst Initiates With Outperform | Benzinga
Ikena Oncology Inc (NASDAQ: IKNA) is garnering attention with its oncology-focused pipeline, and the company's recent developments have raised optimism in the medical community.
Wedbush has initiated coverage on Ikena Oncology with a price target of $11 and an Outperform rating.
Ikena's lead asset, IK-930, is a selective inhibitor of the transcriptional enhanced associate domain (TEAD), a recently validated target in the hippo signaling pathway that currently has limited competition.
IK-930 is currently being evaluated in a Phase 1 monotherapy study, focusing on ...